Build Back Better Could Be... Better in 2022

Tradier  |

Image: President Joe Biden talks on the phone with US Senator Joe Manchin about the Build Back Better agenda, October 22, 2021. Source: Official White House Photo by Adam Schultz.

Build Back Better May Not Be Dead Just Yet

On Sunday, December 19, West Virginia Senator Joe Manchin dropped a bomb on the Biden administration when he said he would not support the $1.9 trillion Build Back Better legislation. With a 50-50 split in the Senate, a no vote from a Democrat was a death knell for the pending program. The senator cited rising inflation as a reason why the US cannot afford to spend another almost $2 trillion after the cost of the legislation would not be covered by tax hikes.

While Republicans cheered, the move angered many Democrats as the legislation is the cornerstone of the President’s campaign pledges. As we move forward into 2022, the Build Back Better legislation has suffered a blow, but it could yet make a comeback.

Politics is the art of negotiation

  • No does not necessarily mean no in politics.
  • Henry Clay, the great compromiser and US Senator from the 1800s, said that the perfect compromise is when both sides of a negotiation walk away from the table with a deal that makes each unhappy.

Subscribe to get our Daily Fix delivered to your inbox 5 days a week

President Biden and Senator Manchin continue to look for a common path: They agree on tax hikes

  • Many Democrats are furious with Senator Manchin.
  • As a former Senator, President Biden has continued to talk with Senator Manchin to find a path for agreement.
  • The President and the West Virginia Democrat agree that taxes need to increase on the wealthiest Americans.
  • Spending is the issue - The President and Senator have not closed the door on negotiations as we head into 2022.

Another Senator from the President’s party objects to tax hikes

  • The administration needs all fifty votes from Democrats in the Senate to pass the BBB legislation.
  • An agreement with Senator Manchin may not be enough.
  • Arizona Senator Kyrsten Sinema objects to increasing taxes.

Raising taxes in an election year could be an issue for the majority party

  • With the mid-term elections in 2022, increasing taxes could be a difficult pill for voters to swallow.
  • Moreover, any attempt at a retroactive tax hike could cause carnage for the majority party in the elections, handing control to the opposition party for the second half of the administration’s first term.

Markets have already digested higher tax rates. Any changes could cause a lot of volatility

  • Markets have already prepared for higher interest and tax rates in 2022.
  • A situation where BBB fails and taxes remain unchanged could lift the stock market despite interest rate hikes.
  • A smaller BBB legislation requiring fewer tax hikes could have a similar impact on stocks.
  • Stocks are going into 2022 in a bullish trend, with the leading indices at or near record highs. The trend is always your best friend in markets across all asset classes.

Thanks for reading, and stay tuned for the next edition of the Tradier Rundown!

Click Here to see why active traders use Tradier Inc.


Equities News Contributor: Tradier Inc.

Source: Equities News

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility
Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market

Market Movers

Sponsored Financial Content